BRPI0719182A2 - Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b - Google Patents

Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b

Info

Publication number
BRPI0719182A2
BRPI0719182A2 BRPI0719182-0A2A BRPI0719182A BRPI0719182A2 BR PI0719182 A2 BRPI0719182 A2 BR PI0719182A2 BR PI0719182 A BRPI0719182 A BR PI0719182A BR PI0719182 A2 BRPI0719182 A2 BR PI0719182A2
Authority
BR
Brazil
Prior art keywords
dislipidemic
omega
levels
agent
fatty acids
Prior art date
Application number
BRPI0719182-0A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Roelof M L Rongen
Robert A Shalwitz
Douglas Kling
Ralph T Doyle Jr
Original Assignee
Reliant Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reliant Pharmaceuticals Inc filed Critical Reliant Pharmaceuticals Inc
Publication of BRPI0719182A2 publication Critical patent/BRPI0719182A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0719182-0A2A 2006-10-10 2007-10-10 Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b BRPI0719182A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85028006P 2006-10-10 2006-10-10
PCT/US2007/021631 WO2008045465A1 (fr) 2006-10-10 2007-10-10 Acides gras oméga-3 et agent dyslipidémique pour la réduction des niveaux d'apo-b

Publications (1)

Publication Number Publication Date
BRPI0719182A2 true BRPI0719182A2 (pt) 2014-10-21

Family

ID=39283166

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719182-0A2A BRPI0719182A2 (pt) 2006-10-10 2007-10-10 Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b

Country Status (10)

Country Link
EP (1) EP2089014A4 (fr)
JP (1) JP2010505956A (fr)
KR (1) KR20090080070A (fr)
CN (2) CN101553221A (fr)
AU (1) AU2007307007A1 (fr)
BR (1) BRPI0719182A2 (fr)
CA (1) CA2672919A1 (fr)
EA (2) EA018734B1 (fr)
MX (1) MX2009003921A (fr)
WO (1) WO2008045465A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
JP2010506920A (ja) * 2006-10-18 2010-03-04 リライアント・ファーマシューティカルズ・インコーポレイテッド Ｌｐ−ｐｌａ２濃度を減少させるためのオメガ−３脂肪酸
EP4137128A1 (fr) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Composition pharmaceutique contenant de l'acide eicosapentaénoïque et leurs procédés d'utilisation
NZ594395A (en) 2009-02-10 2014-01-31 Amarin Pharmaceuticals Ie Ltd Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX2011011538A (es) 2009-04-29 2012-06-13 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
SI3318255T1 (sl) 2009-06-15 2021-07-30 Amarin Pharmaceuticals Ireland Limited Kompozicije in metode za zdravljenje kapi pri subjektu, ki prejema sočasno zdravljenje s statinom
CA2775339C (fr) 2009-09-23 2017-03-28 Amarin Corporation Plc Composition pharmaceutique comportant de l'acide gras omega-3 et derive hydroxy d'une statine et procedes d'utilisation de ceux-ci
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
AU2011336856A1 (en) 2010-11-29 2013-07-04 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013103958A1 (fr) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour abaisser les taux de crp à haute sensibilité (hs-crp) chez un sujet
MX2020013922A (es) 2012-06-29 2022-08-15 Amarin Pharmaceuticals Ie Ltd Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
CN102824636A (zh) * 2012-08-15 2012-12-19 四川大学 一种含他汀类药物和多不饱和脂肪酸的药物组合物及其用途
WO2014034871A1 (fr) * 2012-08-30 2014-03-06 株式会社 三和化学研究所 Médicament pour la prévention ou le traitement de la dyslipidémie
WO2014074552A2 (fr) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour diminuer les triglycérides sans augmenter les taux de ldl-c chez un sujet traité en même temps par la statine
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
DK3102212T3 (en) * 2014-02-05 2019-02-11 Dezima Pharma B V Cholesteryl ester transfer protein (CETP) inhibitors and pharmaceutical compositions comprising the inhibitor for use in the treatment or prevention of cardiovascular disease
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (fr) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions et méthodes pour dimunuer les triglycérides chez un sujet ayant une fonction rénale réduite
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014359A1 (fr) * 2001-03-16 2004-02-19 Thomas Jefferson University Regulation d'apob permettant le traitement et le criblage de medicaments pour des troubles ou des syndromes cardiovasculaires et metaboliques
EA014420B1 (ru) * 2004-12-06 2010-12-30 Релайэнт Фармасьютикалз, Инк. Омега-3 жирные кислоты и дислипидемический агент для липидной терапии
MX2008000915A (es) * 2005-07-18 2008-04-04 Reliant Pharmaceuticals Inc Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos.

Also Published As

Publication number Publication date
WO2008045465A1 (fr) 2008-04-17
MX2009003921A (es) 2009-08-31
KR20090080070A (ko) 2009-07-23
EP2089014A1 (fr) 2009-08-19
EA200970360A1 (ru) 2009-10-30
CN101553221A (zh) 2009-10-07
EA018734B1 (ru) 2013-10-30
CN101553220A (zh) 2009-10-07
AU2007307007A1 (en) 2008-04-17
CA2672919A1 (fr) 2008-04-17
JP2010505956A (ja) 2010-02-25
EP2089014A4 (fr) 2009-12-09
EA200970359A1 (ru) 2009-10-30

Similar Documents

Publication Publication Date Title
BRPI0719182A2 (pt) Ácidos graxos omega 3 e agente dislipidêmico para redução de níveis de apo-b
EP2299998A4 (fr) Acides gras à chaînes de longueur moyenne et glycérides agents néphroprotecteurs
EP2083815A4 (fr) Statine et acides gras oméga-3 pour la réduction des niveaux d'apo-b
BRPI0921467A8 (pt) enzimas e métodos para produzir ácidos graxos ômega-3
DK1385498T3 (da) Fedtsyrer som overlevelses- og aktiveringsfaktorer for neutrofiler
IL192366A0 (en) Omega 3 fatty acid formulations
EP1723096A4 (fr) Triglycerides structures et emulsions contenant ces triglycerides
EP1830830A4 (fr) Acides gras omega-3 et agent dyslipidemique pour therapie lipidique
CL2007003761A1 (es) Composicion liquida de limpieza personal que comprende isetionatos de acilo graso, cosurfactante, alcanolamida y/o alquilaminaoxido, acidos grasos de cadena recta o mezcla con alcoholes grasos de cadena recta y/o aceites de hidrocarburo alifatico, la
BRPI0717027A2 (pt) Hidrocarbonetos e ácidos graxos de cadeias de comprimento médio de algas
BRPI0716439A2 (pt) formulaÇÕes de flibanserina e mÉtodo para fabricaÇço das mesmas.
BRPI0911606A2 (pt) Polipeptídeo e métodos para produzir triacilgliceróis compreendendo ácidos graxos modificados
BRPI0719594A2 (pt) Partícula de liberação contendo agente de benefício
DE502005004091D1 (de) Emulsionen mit ungesättigten Fettsäuren und deren Estern
BRPI0719849A2 (pt) Método de imunização contra os quatro sorotipos da dengue
BRPI0816640A2 (pt) "método para produzir produtos de proteína estável ácida e produtos assim produzidos"
PT1418225E (pt) Agente desinfectante e desodorizante para sanitas
IL190728A0 (en) Intravenous essential fatty acid emulsion
BRPI0819026A2 (pt) "método para produzir um gel aquoso de adapaleno e gel aquoso de adapaleno"
BRPI0716765A2 (pt) mÉtodos e composiÇÕes para administrar agentes hipoglicÊmicos de longa duraÇço
PL1765318T3 (pl) Średniołańcuchowe kwasy tłuszczowe przydatne jako środki przeciwdrobnoustrojowe
ITMI20051371A1 (it) Dispositivo e procedimento per la tempra termica di oggetti oblunghi cavi
BRPI0813074A2 (pt) "processo de preparação de ésteres de ácidos graxos e processo de preparação de bagaços"
BRPI0916672A2 (pt) método para fabricação de um núcleo absorvente tendo uma pluralidade de primeiras regiões e uma segunda região circundando cada uma das primeiras regiões
CL2004001004A1 (es) Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple.

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 60/850,280 DE 10/10/2006 REIVINDICADA NO PCT/US2007/021631, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 29 DA RESOLUCAO INPI-PR 77/2013. OBSERVA-SE QUE A PRIORIDADE US 60/850,280 DE 10/10/2006 POSSUI COMO TITULAR "ROELOF M. L. RONGEN" E "ROBERT A. SHALWITZ". ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT ("RELIANT PHARMACEUTICALS, INC.") SER DISTINTO DAQUELE QUE DEPOSITOU A PRIORIDADE REIVINDICADA E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.

B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]